The AMPLITUDE Trial — PARP Inhibition Moves Upstream in HRR-Deficient mCSPC

Johnson & Johnson want Niraparib in the hormone-sensitive BRCA-altered prostate cancer setting based on PFS — efficacy signal, but fundamental design flaws remain.